Composition for preventing the occurrence of cardiovascular event in multiple risk patient

Abstract

Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.

What is claimed: 
     
         1 . A method of reducing occurrence of a cardiovascular event in a hypercholesterolemia patient comprising,
 identifying a patient having triglycerides (TG) of at least 150 mg/DL and HDL-C of less than 40 mg/dL in a blood sample taken from the patient as the only risk factor of a cardiovascular event, wherein the patient has not previously had a cardiovascular event, and administering ethyl icosapentate in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor,   wherein the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor is selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin, and salts thereof; and   wherein the patient has hypercholesterolemia.   
     
     
         2 . The method according to  claim 1 , wherein said 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor is administered to the patient at least one of before, during and after administering the ethyl icosapentate. 
     
     
         3 . The method according to  claim 1 , wherein the patient has at least one risk factor selected from the group consisting of obesity, hypertension, prehypertension, diabetes, prediabetes, and abnormal glucose tolerance. 
     
     
         4 . The method according to  claim 1 , wherein the patient has at least two risk factors selected from the group consisting of obesity, hypertension, prehypertension, diabetes, prediabetes, and abnormal glucose tolerance. 
     
     
         5 . The method according to  claim 1 , wherein the ethyl icosapentate is administered daily for two years or more. 
     
     
         6 . The method according to  claim 1 , wherein the ethyl icosapentate is orally administered at a dose of 0.3 g/day to 6 g/day. 
     
     
         7 . The method according to  claim 6 , wherein the ethyl icosapentate is orally administered at a dose of 1.8 g/day to 2.7 g/day. 
     
     
         8 . The method according to  claim 1 , wherein the patient is a male patient. 
     
     
         9 . The method according to  claim 1 , wherein the content of the ethyl icosapentate is at least 96.5% by weight in relation to the total content of fatty acid that is simultaneously administered with the ethyl icosapentate. 
     
     
         10 . The method according to  claim 2 , wherein the ethyl icosapentate is in an amount of 600-900 mg per administration. 
     
     
         11 . The method according to  claim 9 , wherein the ethyl icosapentate is in an amount of 600-900 mg per administration.